Oncolytics Biotech Inc T.ONC

Meta Study

[lonc17]

No news here - we have known for ages that Pelareorep is a dud in many indications and with many drug combinations.

But it is interesting timing for this Meta Study to appear. There must be some underlying reason for people to waste time publishing old news.

It certainly does little to instill confidence in the promised breast cancer phase 3. I'll be very suprised if that ever gets launced.

Really, the last kick at the can after 20+ years of failed results is now ESMO and PanCAN.

I think ONC should fire 90% of their staff, reduce expenses by half and hold tight till the first pancreatic data comes out in about three years.

[lonc17]

Here's the link: https://www.frontiersin.org/articles/10.3389/fphar.2023.1228225/abstract

[Buckhenry]

Will someone tell unnoteable the ship has sailed and pela is not on it so shut up and quit posting your garbage. 

[Azzak34]

Uh oh, someone doesn't understand the MOA of Pela or get the need for combo therapies. You should put the peanut butter down and give the dog the night off then read some more. What a dummy! 

[Noteable]

A Chinese derived publication that obscurely referred to chemotherapy in a general way and did not specify which chemotherapy they were citing  given that we now know through the BRACELET-1 study that paclitaxel (chemotherapy) in combination with pelareorep is an effective combination in comparison to paclitaxel alone. This drive-by is similar to the SeekingAlpha hatchet piece released last